This year’s World CML Day coincided with the recent publication of clinical data of olverembatinib (HQP1351) in the prestigious oncology journal, the Journal of Hematology & Oncology.
Prof. Hagop Kantarjian, Chairman of the Department of Leukemia at MD Anderson Cancer Center, shared his thoughts on the eve of World CML Day.
Click to watch the below video from Prof. Kantarjian.
September 22nd was chosen as the date of the World CML Day because Chronic Myeloid Leukemia (CML) is a disease driven by the BCR-ABL fusion gene induced by the translocation of human chromosome 9 and 22.
Recently, results from a Phase I/II study of olverembatinib in patients with CML were published in the prestigious oncology journal, the Journal of Hematology & Oncology. The publication of these results demonstrated olverembatinib’s potential as a China-developed novel therapy for patients with CML worldwide.
On this important day, Prof. Hagop Kantarjian, MD, Chairman of the Department of Leukemia at MD Anderson Cancer Center, shared his views on the current treatment landscape and clinical challenges in the treatment of CML. He also discussed the therapeutic potential of olverembatinib. Concluding his presentation, Prof. Kantarjian expressed his hope that olverembatinib can soon become available to patients around the world.
MD Anderson Cancer Center is one the world’s most recognized medical centers in oncology and the research and treatment of leukemia. As one of the global leaders in the field of blood cancer, Prof. Kantarjian has made enormous contributions to the clinical advances in CML, most noticeably by leading the clinical development of all three generations of TKIs in the US.
精彩评论